World Hepatitis D Epidemiology and Market Outlook to 2030, Featuring MYR Pharmaceuticals/Hepatera, Eiger Biopharmaceuticals and Janssen Biopharmaceuticals

Dublin, March 10, 2021 (GLOBE NEWSWIRE) -- The "Hepatitis D - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to's offering.

This report delivers an in-depth understanding of the HDV, historical and forecasted epidemiology as well as the HDV market trends in the United States, EU5 and Japan.

The HDV market report provides current treatment practices, emerging drugs, HDV market share of the individual therapies, current and forecasted HDV market size from 2017 to 2030. The report also covers current HDV treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Scope of the Report

  • The report covers the descriptive overview of HDV, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the HDV epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for HDV is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the HDV market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global HDV market.

Report Highlights

  • In the coming years, the HDV market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence HDV R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for HDV. The launch of emerging therapies will significantly impact the HDV market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for HDV.
  • In-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions Answered

Market Insights:

  • What was the HDV Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the HDV total market size as well as market size by therapies across the 7MM during the study period (2017-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest HDV market size during the study period (2017-2030)?
  • At what CAGR, the HDV market is expected to grow in the 7MM during the study period (2017-2030)?
  • What would be the HDV market outlook across the 7MM during the study period (2017-2030)?
  • What would be the HDV market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
  • HDV patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration, and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the HDV market?

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of the HDV?
  • What is the historical HDV patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What would be the forecasted patient pool of HDV in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to HDV?
  • Out of all the 7MM countries, which country would have the highest prevalent population of HDV during the study period (2017-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of HDV?

Companies Mentioned

  • MYR Pharmaceuticals/Hepatera
  • Eiger Biopharmaceuticals
  • Janssen Biopharmaceuticals

For more information about this drug pipelines report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contact Data